Professor Kaye Williams
Professor; Group Leader Hypoxia and Therapeutics
- Email: firstname.lastname@example.org
- Telephone: +44 (0)161 275 2428
- Alternative Telephone: +44 (0)161 275 2487 (Group Secretary)
- Fax: 0161 275 8342
School of Pharmacy & Pharmaceutical Sciences
Leadership and management roles within the University of Manchester are focused upon the promotion and management of research. Specific contributions are made via roles in the following groups:
• Member of the School of Pharmacy and Pharmaceutical Sciences Research Committee reporting to the Research Director for the School. Committee. Remit: strategic and operational role to continually raise the research profile of the School in line with the 2015 vision for the University of Manchester.
• Member of the University of Manchester Biomedical Imaging Institute Oncology Strategy group. Remit: to coordinate and develop oncological imaging, of any modality, across the UoM.
• Member of the University of Manchester Lung Strategy Group. Remit: to develop and implement a strategic plan for lung cancer research within the UoM to achieve international recognition in both pre-clinical and clinical forums.
• Member of the University of Manchester and associated Health Care Trusts Translational Imaging Group. Remit: to facilitate and develop translational imaging programmes across the UoM.
• Member of the University of Manchester Positron Emission Tomography Operational Executive. Remit: To ensure optimal scientific imaging strategies in PET imaging for the UoM and to prioritise, approve and facilitate the development of PET-based clinical and pre-clinical imaging projects.
• Pre-clinical lead of oncology imaging within the Manchester Cancer Research Centre. Remit; to implement the pre-clinical non-invasive imaging strategy within the MCRC.
• Member of the Manchester Cancer Research Centre Radiation Related Research Implementation Team. Remit: to raise the profile of radiation related research within the MCRC to an internationally competitive position.
Memberships of Committees and Professional Bodies
- Chair of the British Institute of Radiology, Radiation and Cancer Biology Committee
- President; Association of Radiation Research
- Trustee of the LH Gray Memorial Trust
- Member of the National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group
- British Association for Cancer Research
- European Association for Cancer Research
- American Association for Cancer Research
- Association of Radiation Research
- Radiation Research Society
- British Institute of Radiology
Kaye currently leads an integrated and multi-disciplinary team whose overall goal is to exploit tumour hypoxia and the factors that govern cellular response to this tumour specific micro- environmental stress for therapeutic benefit. Specific avenues of Kaye’s research have focussed upon the contribution of the transcription factor hypoxia inducible factor-1 (HIF-1) to tumour growth and response to therapy both in vitro and in vivo. Novel findings from these studies have highlighted HIF-1 as a key target for anti-cancer therapeutic design and in particular have provided a rationale for the application of HIF-1 targeted therapies in combination with conventional chemo and/or radiotherapy. In addition to using HIF-1 targeted approaches Kaye also has a keen interest in the use of other molecular targeted therapies in combination with radiation treatment. In particular she has investigated the impact of novel agents on the underlying mechanisms that govern radiation response to enable their optimal application in a clinical radiotherapy context. Recently, Kaye has taken a lead role in the development of pre-clinical imaging for oncology applications within the Manchester Cancer Research Centre. The focus here is to develop, validate and apply image derived biomarkers to assess changes in tumour biology and therapeutic response.
If you would like to apply for a PhD under the supervision of Dr Williams, please visit this page.
- Year 1. Foundation Biology
- Year 2. Inter-Professional Education
- Year 4. Cancer Biology and Therapy
- Academic Advisor : 26 Advisees Years 1-4
- Fourth year MPharm Research Project Supervisor
• FMHS generic skills training for PhD students: Facilitator for various modules
External Teaching and Assessment
• Biological Basis of Cancer Therapy Course (Royal College accredited Training Course for Clinical and Medical Oncology Specialist Registrars covering FRCR part 1 examination syllabus), Christie Hospital NHS Trust, Manchester.
• MSc Oncology, Tumour Physiology Module, University of Nottingham. Teaching lecture “Tumour Hypoxia”.
• MSc Oncology, Radiation Sciences for the Clinical and Medical Oncologist, The Institute of Cancer Research, London. Teaching lecture “Hypoxia and Radiation”
• MSc Radiation Biology, University of Oxford, teaching lectures in hypoxia and radiobiology
• Member of the examining board for the first FRCR examination in Clinical Oncology
Professor Kaye Williams is the Leader of the Hypoxia and Therapeutics Group within the School of Pharmacy and Pharmaceutical Sciences. Kaye joined the Experimental Oncology division in November 1996 upon completion of PhD studies. Following back-to-back Research Associate and Research Fellow positions funded by the Medical Research Council, she gained a tenured Senior Lecturer position in January 2006 and Reader in July 2010. Her group currently focuses upon the tumour microenvironment, investigating therapeutic targets, vascular biology and molecular interactions. She also leads pre-clinical imaging development within the Manchester Cancer Research Centre.
Kaye was awarded the British Association for Cancer Research/AstraZeneca Frank Rose Young Scientist Award in 2005.
- 1997 - PhD Faculty of Medicine - University of Manchester
- 1993 - BSc (Hons) Molecular Biology - First Class, School of Biological Sciences, University of Manchester
Collaborators and affiliated staff
Dr Roben Gieling- Post-doctoral Reseacher
Dr Chris Cawthorne- Post-doctoral Researcher
Mr Muhammad Babur- Research Technician
Mr Brian Telfer- Experimental Officer
Ms Natalie Burrows- PhD student
Ms Janet Kinnersley- PhD student
Ms Emily Armitage- PhD student
Dr Costas Demonacos - Molecular Pharmacology, redox sensitive transcriptional regulation
Professor Caroline Dive- Mechanisms of hypoxia-mediated modification of chemotherapy response
Professor Ian Stratford- Tumour biology
Professor Georg Brabant- Role of hypoxia in thyroid carcinoma
Dr Adam McMahon- Integration of imaging and proteomic tools
Professor Anne White- Endocrine tumour biology
- 1. Natalie Burrows, Muhammad Babur, Julia Resch, Sophie Ridsdale, Melissa Mejin, Georg Brabant and Kaye J Williams. (2011). GDC-0941 Inhibits Metastatic Characteristics of Thyroid Carcinomas by Targeting both the Phosphoinositide-3 Kinase (PI3K) and Hypoxia-Inducible Factor-1α (HIF-1α) Pathways. The Journal of Clinical Endocrinology & Metabolism, 96(12), e1934-1943. eScholarID:140736 | DOI:10.1210/jc.2011-1426
- 4. Monika Golinska, Helen Troy, Yuen-Li Chung, Paul MJ McSheehy, Manuel Mayr, Xiaoke Yin, Lucy Ly, Kaye J Williams, Rachel Airley, Adrian L Harris, John Latigo, Meg Perumal, Eric Aboagye, David Perrett, Marion Stubbs and John R Griffiths. (2011). Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas. BMC Cancer, 11(198), 1-13. eScholarID:140737 | DOI:10.1186/1471-2407-11-198
- Burrows N, Resch J, Babur M, Brabant GE and Williams KJ. (2011). Hypoxia-inducible factor (HIF) in thyroid carcinoma. Journal of Thyroid Research. Journal of Thyroid Research, 2011, 1-17. eScholarID:140739 | DOI:10.4061/2011/762905
- Majid Ali, Marzieh Kamjoo, Huw D Thomas, Suzanne Kyle, Ivanda Pavlovska, Muhammed Babur, Brian A Telfer, Nicola J Curtin and Kaye J Williams. (2011). The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but doesn’t enhance the efficacy of doxorubicin, despite improving tumour perfusion and radiation response in mice. Mol Cancer Therapeutics, 10(12), 2320-2329. eScholarID:140738 | DOI:10.1158/1535-7163.MCT-11-0356
- Burrows N, Resch J, Cowen RL, von Wasielewski R, Hoang-Vu C, West CM, Williams KJ, Brabant G. (2010). Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr Relat Cancer, 17(1), 61-72. eScholarID:76766 | DOI:10.1677/ERC-08-0251
- Lunt, S., Cawthorne, C., Ali, M., Telfer, B., Babur, M., Smigova, A., Julyan, P., Price, P., Stratford, I., Bloomer, W., Papadopoulou, M. & Williams, K (2010). The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy. Br J Cancer, 103, 201-208. eScholarID:86071 | PMID:20588272 | DOI:10.1038/sj.bjc.6605753
- Sommer P, Cowen RL, Berry A, Cookson A, Telfer BA, Williams KJ, Stratford IJ, Kaye P, White A, Ray DW. (2010). Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumour growth. Endocrine-Related Cancer, 17, 203-213. eScholarID:76836 | DOI:10.1677/ERC-09-0241
- Ali, M., Telfer, B., McCrudden, C., O'Rourke, M., Thomas, H., Kamjoo, M., Kyle, S., Robson, T., Shaw, C., Hirst, D., Curtin, N. & Williams, K (2009). Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo? Clinical cancer research, 15(19), 6106. eScholarID:74292 | PMID:19789326 | DOI:10.1158/1078-0432.CCR-09-0398
- Roberts, D., Williams, K., Cowen, R., Barathova, M., Eustace, A., Brittain-Dissont, S., Tilby, M., Pearson, D., Ottley, C., Stratford, I. & Dive, C (2009). Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br J Cancer, 101(8), 1290-7. eScholarID:74293 | PMID:19755992 | DOI:10.1038/sj.bjc.6605311
- Shannon AM, Telfer BA, Smith PD, Babur M, Logie A, Wilkinson RW, Debray C, Stratford IJ, Williams KJ* and Wedge SR. (2009). The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts. Clinical Cancer Research, 15(21), 6619-6629. eScholarID:78745 | DOI:10.1158/1078-0432.CCR-08-2958
- McKeown S, Cowen RL, Williams KJ. (2007). Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol), 19( 6), 427-42. eScholarID:1d15971
- Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge S. (2007). Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol Cancer Ther, 6( 2), 599-606. eScholarID:1d15229
- Brown L M, Cowen RL, Debray C, Eustace A, Erler J T, Sheppard FC.D, Parker C A, Stratford IJ, Williams KJ. (2006). Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol.Pharmacol, 69, 411-418. eScholarID:1d12742